Objective: Borderline epithelial ovarian tumors have good prognosis without any adjuvant therapy. The advantage of aggressive surgical staging, especially retroperitoneal lymph node sampling is questionable in patients with borderline ovarian tumors. We designed this study to evaluate the necessity of retroperitoneal pelvic and para-aortic lymph node dissection in the treatment of borderline epithelial ovarian tumors.
Study Design: From 1998 to 2007, 57 women who were diagnosed with borderline epithelial ovarian tumor in our hospital were prospectively accrued and evaluated; 27 of them (47.3%) had full surgical staging procedure including para-aortic and pelvic node dissection. Student's t-test was used to compare follow-up times.
Results: Median follow-up time was 54.6 (12-96) months for all patients in the study. There was one recurrence of disease, which was in the complete staging group. Follow-up times of patients were not statistically different between lymph node evaluated and non-evaluated groups (p = 0.10). We did not find any metastasis in lymph nodes in 27 women who had complete surgical staging procedure.
Conclusion: Patients with borderline epithelial tumors who had full surgical staging procedure do not have survival advantage over those who had no lymph node evaluation and yet were patients with malignant ovarian tumors.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00404-007-0478-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
MUC1 and glycan probing of CA19-9 captured biomarkers from cyst fluids and serum provides enhanced recognition of ovarian cancer.
Sci Rep
January 2025
Department of Life Technologies, Division of Biotechnology, University of Turku, Medisiina D, 5th floor, Kiinamyllynkatu 10, 20520, Turku, Finland.
Glycosylation changes of circulating proteins carrying the CA19-9 antigen may offer new targets for detection methods to be explored for the diagnosis of epithelial ovarian cancer (EOC). Search for assay designs for targets initially captured by a CA19-9 antigen reactive antibody from human body fluids by probing with fluorescent nanoparticles coated with lectins or antibodies to known EOC associated proteins. CA19-9 antigens were immobilized from ascites fluids, ovarian cyst fluids or serum samples using monoclonal antibody C192 followed by probing of carrier proteins using anti-MUC16, anti-MUC1 and, anti STn antibodies and seven lectins, all separately coated on nanoparticles.
View Article and Find Full Text PDFEvaluation of the Clinicopathological Features Associated With Malignancy of Phyllodes Tumor of the Breast.
Cureus
December 2024
Department of Medicine, ASEAB (Association for Socio-Economic Advancement of Bangladesh) Community Hospital and Diagnostic Center, Pabna, BGD.
Objective: Phyllodes tumor (PT) is a variant of fibroepithelial proliferations of the breast, histologically demonstrating a leaf-like pattern. The WHO has categorized PTs as benign, borderline, or malignant based on their histological characteristics. The objective of this paper is to assess the clinicopathological factors with malignancy in PT of the breast.
View Article and Find Full Text PDFDeep Learning Radiomics Nomogram Based on MRI for Differentiating between Borderline Ovarian Tumors and Stage I Ovarian Cancer: A Multicenter Study.
Acad Radiol
January 2025
Department of Radiology, the Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, Jiangsu, China (X.W., X.C., Y.C., S.C., M.W.). Electronic address:
Rationale And Objectives: To develop and validate a deep learning radiomics nomogram (DLRN) based on T2-weighted MRI to distinguish between borderline ovarian tumors (BOTs) and stage I epithelial ovarian cancer (EOC) preoperatively.
Materials And Methods: This retrospective multicenter study enrolled 279 patients from three centers, divided into a training set (n = 207) and an external test set (n = 72). The intra- and peritumoral radiomics analysis was employed to develop a combined radiomics model.
Histopathological spectrum of ovarian tumors in Jharkhand, India: A retrospective study.
J Family Med Prim Care
December 2024
Histopathology, Department of Pathology, Rajendra Institute of Medical Sciences, Ranchi, Jharkhand, India.
Background: Ovarian tumors are the most prevalent neoplasms worldwide, affecting women of all ages. According to Globocan's 2022 projections, by 2050, the number of women diagnosed with ovarian cancer worldwide will increase by over 55% to 503,448. The number of women dying from ovarian cancer is projected to increase to 350,956 each year, an increase of almost 70% from 2022.
View Article and Find Full Text PDFExpanding the Range of Epithelial Marker and SMA Staining of Superficial CD34+ Fibroblastic Tumors: A Case Report and Review of the Literature.
Am J Dermatopathol
December 2024
Departments of Dermatology and Pathology, University of California, Irvine, CA.
Superficial CD34+ fibroblastic tumor (SCD34FT) is a relatively recently described borderline mesenchymal neoplasm. Owing to a relative lack of specificity in clinical presentation, radiopathologic findings, and immunohistochemical staining, the diagnoses of SCD34FT can be challenging. In this study, we present a case of a 55-year-old woman with an indolent painless nodule on the right shin.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!